Obtain Favorable Decision In Patent Infringement Litigation Related To Lenvatinib In The U.S.
29/05/2025 24:35
Eisai Co Ltd 4523.T: EISAI CO LTD - OBTAIN FAVORABLE DECISION IN PATENT INFRINGEMENT LITIGATION RELATED TO LENVATINIB IN THE U.S. EISAI CO LTD - SHILPA NOW IS NOT ABLE TO RECEIVE APPROVAL FROM FDA TO SELL ITS GENERIC VERSION OF LENVATINIB MESYLATE UNTIL AFTER THE PATENT AND RELATED EXCLUSIVITY EXPIRES IN FEBRUARY 2036 Source text: ID:nTSqb8b666 Further company coverage: 4523.T
Recent news on Shilpa Medicare
See all newsBrief: Shilpa Medicare Q2 Consol Net Profit INR 791.8 Million
Brief: Shilpa Medicare Says USFDA Conducts Surveillance Inspection At Shilpa Medicare Unit
Brief: Shilpa Medicare Receives Final SEC Approval For Oeris Marketing Authorization
India's Shilpa Medicare gains on approval for OERIS
Brief: Shilpa Medicare Initiates Voluntary Recall Of 27,923 Pemetrexed Injection Vials In Us On July 29, 2026